Navigation Links
Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Date:6/2/2009

MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that Qnexa data will be featured in two podium presentations during the 69th Scientific Sessions of the American Diabetes Association (ADA), being held from June 5-9, 2009 in New Orleans, Louisiana. Previous studies have shown significant weight loss with Qnexa treatment. Both podium presentations will highlight the benefit of weight loss and the corresponding positive impact on type 2 diabetes. Data from the phase 3 EQUATE trial (OB-301) shows that weight loss with Qnexa stops the progression of type 2 diabetes in obese, non-diabetic patients. The results of a year-long phase 2 diabetic study, DM-230, demonstrate that weight loss with Qnexa can significantly lower blood sugar in type 2 diabetics.

"Obesity and type 2 diabetes, which are inextricably linked, are growing at epidemic proportions worldwide and physicians need new, more effective treatment options for the millions of patients at risk," commented Leland Wilson, president and chief executive officer of VIVUS. "In clinical studies to date, Qnexa has demonstrated significant impact on patients' weight, glucose levels, HbA1c and other critical cardiovascular risk factors, in patients with and without diabetes. We are delighted that Qnexa data from our previously reported phase 3 obesity study and our previously reported year-long diabetes study have been selected for podium presentations at the ADA annual meeting."

Details for the two oral podium presentations of Qnexa data follow:

Date and Time: Saturday, June 6, 2009, 4:00-6:00 P.M.

Session: Novel Diabetes Treatments in Development in Humans

Presentation Title: Weight Loss with VI-0521 (Qnexa) Stops Progression Towards Type 2 Diabetes in Obese Non-Diabetic Subjects

Abstract: 119-OR

Location: Louisiane C, Morial Convention Center

Presenter: Louis J. Aronne, MD

Date and Time: Monday, June 8, 2009, 4:30-6:30 P.M.

Session: New Treatments in Development

Presentation Title: One Year Treatment with VI-0521(Qnexa) in Type 2 Diabetes Demonstrates Continued Glycemic Improvement and Weight Loss

Abstract: 361-OR

Location: Hall E-2, Morial Convention Center

Presenter: W. Timothy Garvey, MD

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.

CONTACT:

    VIVUS, Inc.

    Timothy E. Morris
    Chief Financial Officer
    650-934-5200


    Investor Relations:  The Trout Group
                         Brian Korb
                         646-378-2923

    Public Relations:    Pure Communications, Inc.
                         Jennifer Torres
                         312-624-9802


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
6. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
7. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
8. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
9. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
10. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/21/2016)... 2016 Unique technology combines ... superior security   Xura, Inc. ... secure digital communications services, today announced it is working ... enterprise customers, particularly those in the Financial Services Sector, ... authentication within a mobile app, alongside, and in combination ...
Breaking Biology News(10 mins):